New hope for advanced colon cancer: drug combo trial launches
NCT ID NCT07042685
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial is testing a combination of the targeted drug fruquintinib with standard chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. Fifty participants will receive the drugs in 28-day cycles, with the goal of seeing how long the cancer stays under control. The study is currently recruiting at Houston Methodist hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib combined with 5-fluorouracil-based chemotherapy (FOLFIRI or mFOLFOX6)
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced colorectal cancer, potentially slowing disease progression.
What could go wrong
This is an early Phase II trial with only 50 participants, so results may not apply to everyone. Side effects from the drug combination could be significant, and the treatment may not work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••